SCHEMBL3982260

SCHEMBL3982260

CS(C)(=O)=NC(=O)Nc1cc(N)ccc1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 9/20 0.42
▸ PDGFRB P09619 5/20 0.42
▸ ALDH1A1 P00352 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ NPC1 O15118 2/20 0.37
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ EIF2AK2 P19525 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ MAPT P10636 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CA12 O43570 2/20 0.34
▸ CASR P41180 1/20 0.34
▸ TEK Q02763 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ GLA P06280 1/20 0.34
▸ PLA2G7 Q13093 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986789 0.84 L3MBTL1 (0.40) ALDH1A1TSHRCA1CA2CA9
SCHEMBL3979264 0.82 HSD17B10 (0.47) ALDH1A1TSHRNPC1CA1CA2
SCHEMBL14259864 0.81 ALDH1A1 (0.40) KDRPDGFRBALDH1A1LMNATSHR
SCHEMBL3986842 0.80 RAD52 (0.50) ALDH1A1TSHRCA1CA2CA9
SCHEMBL3979152 0.78 ALDH1A1 (0.56) ALDH1A1LMNACA1CA2CA9
SCHEMBL3985472 0.77 MAPT (0.51) ALDH1A1NPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3982267 0.77 LMNA (0.38) KDRPDGFRBALDH1A1LMNATSHR
SCHEMBL29664617 0.76 NPC1 (0.50) ALDH1A1NPC1CA1CA2CA9
SCHEMBL3785537 0.76 NPC1 (0.50) ALDH1A1NPC1CA1CA2CA9
SCHEMBL18332101 0.76 KDM1A (0.51) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2059511-A1 SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS Bayer Schering Pharma Aktiengesellschaft (DE) 2009-05-20 — — EP disclosed
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors BAYER SCHERING PHARMA AG (DE) 2008-07-10 — — US disclosed
WO-2008025556-A1 SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-06 — — WO disclosed
WO-2008025556-A1 SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167330-A1 Carbamoylsulphoximides as protein kinase inhibitors CABLES1, CKS2, CDK2AP1 KDR 2279/4885PDGFRB 1308/4885ALDH1A1 1535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback